Case reports reveal palpitations and musculoskeletal pain in patients using tirzepatide, suggesting postmarketing scrutiny is crucial.
Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separately. The case reports presented here, detailing palpitations, musculoskeletal pain, and headaches following tirzepatide administration, raise important questions about the drug's postmarketing safety profile.
No takes yet. Share an insight, caveat, or question.
Colorado et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: